ADC Therapeutics SA (ADCT)
NYSE: ADCT · Real-Time Price · USD
3.425
-0.165 (-4.60%)
Jun 4, 2025, 2:02 PM - Market open
ADC Therapeutics Stock Forecast
Stock Price Forecast
According to 4 professional analysts, the 12-month price target for ADC Therapeutics stock ranges from a low of $7.00 to a high of $8.00. The average analyst price target of $7.75 forecasts a 126.28% increase in the stock price over the next year.
Price Target: $7.75 (+126.28%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ADC Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Reiterates $8 | Buy | Reiterates | $8 | +133.58% | May 15, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $10 → $7 | Strong Buy | Maintains | $10 → $7 | +104.38% | Mar 31, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +133.58% | Mar 31, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Mar 7, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Maintains $6 → $8 | Buy | Maintains | $6 → $8 | +133.58% | Feb 24, 2025 |
Financial Forecast
Revenue This Year
77.35M
from 70.84M
Increased by 9.19%
Revenue Next Year
89.94M
from 77.35M
Increased by 16.27%
EPS This Year
-1.49
from -1.62
EPS Next Year
-1.38
from -1.49
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 83.8M | 122.4M | 187.6M | ||
| Avg | 77.3M | 89.9M | 151.3M | ||
| Low | 69.1M | 71.1M | 127.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 18.3% | 58.3% | 108.6% | ||
| Avg | 9.2% | 16.3% | 68.2% | ||
| Low | -2.5% | -8.0% | 41.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.38 | -0.96 | -0.66 |
| Avg | -1.49 | -1.38 | -0.98 |
| Low | -2.21 | -2.05 | -1.52 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.